ClinicalTrials.gg

Program

Probiotic

Also written as “Probiotic (Inersan)”, “R-2487” and “Probiatop”.

Its studies are mostly in Chronic Periodontitis · Sjogren's Syndrome · Depression · Signs and Symptoms, Digestive · Irritable Bowel Syndrome, led by 11 companies.

Furthest: phase 4, since Jun 3, 201314 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CD Pharma India Pvt.30 open or runningphase 3since Jun 3, 2013Jun 3, 2013none ahead
Next Gen Pharma India Pvt.20 open or runningphase 3since Feb 3, 2015Feb 3, 2015none ahead
AbbVie10 open or runningphase 2since Nov 2, 2007Nov 2, 2007none ahead
Azidus Brasil10 open or runningphase 4since Oct 20, 2022Oct 20, 2022none ahead
GenMont Biotech Incorporation10 open or runningphase 2since Sep 22, 2020Sep 22, 2020none ahead
International Flavors & Fragrances10 open or runningphase 2since Aug 30, 2019Aug 30, 2019none ahead
Kaneka10 open or runningphase 1since Feb 26, 2018Feb 26, 2018none ahead
Kerry Group10 open or runningphase 1since Nov 14, 2019Nov 14, 2019none ahead
Lallemand Health Solutions11 open or runningphase 4since Jul 1, 2022Jul 1, 2022none ahead
Moon (Guangzhou) Biotechnology11 open or runningno phasesince Dec 30, 2025Dec 30, 2025Dec 30, 2026NCT07331987
Rise Therapeutics11 open or runningphase 1since Feb 28, 2024Feb 28, 2024Aug 30, 2029phase 1 · NCT06297213

Also a collaborator on its studies: farmoquimica-s-a, icon-plc and 4pharma-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 2, 2007.

  1. Jun 3, 2013CD Pharma India Pvt.'s first study: phase 3 study in Chronic PeriodontitisNew to CD Pharma India Pvt.CD Pharma India Pvt. · NCT01870362 · 28 enrolled · India
  2. Apr 22, 2014Phase 3 study in Chronic PeriodontitisCD Pharma India Pvt. · NCT02121665 · 42 enrolled · India
  3. Jul 28, 2014Phase 3 study in Lymphoma, FollicularCD Pharma India Pvt. · NCT02203812 · 32 enrolled · India
  4. Feb 3, 2015Next Gen Pharma India Pvt.'s first study: phase 3 study in MalocclusionNew to Next Gen Pharma India Pvt.Next Gen Pharma India Pvt. · NCT02357771 · 30 enrolled · India
  5. Mar 11, 2015Phase 3 study in Chronic PeriodontitisNext Gen Pharma India Pvt. · NCT02390687 · 31 enrolled · India
  6. Feb 26, 2018Kaneka's first study: phase 1 study in CariesNew to KanekaKaneka · NCT03468842 · 76 enrolled · Spain
  7. Aug 30, 2019International Flavors & Fragrances's first study: phase 2 study in Stress, PsychologicalNew to International Flavors & FragrancesInternational Flavors & Fragrances · NCT04125810 · 190 enrolled · Ireland, United Kingdom
  8. Nov 14, 2019Kerry Group's first study: phase 1 study in Streptococcus AgalactiaeNew to Kerry GroupKerry Group · NCT04165551 · 3 enrolled · Spain
  9. Sep 22, 2020GenMont Biotech Incorporation's first study: phase 2 study in Skin ProblemsNew to GenMont Biotech IncorporationGenMont Biotech Incorporation · NCT04566549 · 21 enrolled · Taiwan
  10. Jul 1, 2022Lallemand Health Solutions's first study: phase 4 study in Irritable Bowel SyndromeNew to Lallemand Health SolutionsLallemand Health Solutions · NCT05509725 · 162 planned · Turkey
  11. Oct 20, 2022Azidus Brasil's first study: phase 4 study in Signs and Symptoms, DigestiveNew to Azidus BrasilAzidus Brasil · NCT05603403 · 150 enrolled · Brazil
  12. Feb 28, 2024Rise Therapeutics's first study: phase 1 study in Sjogren's SyndromeNew to Rise TherapeuticsRise Therapeutics · NCT06297213 · 36 planned · United States
  13. Dec 30, 2025Moon (Guangzhou) Biotechnology's first study: no phase study in DepressionNew to Moon (Guangzhou) BiotechnologyMoon (Guangzhou) Biotechnology · NCT07331987 · 60 planned · China
  14. Oct 8, 2026Phase 1 study terminatedStudy stoppedNCT04165551 · “The study was terminated due to low enrollment”

Ahead

  1. Dec 30, 2026Primary completion: no phase study in DepressionMoon (Guangzhou) Biotechnology · NCT07331987
  2. Aug 30, 2029Primary completion: phase 1 study in Sjogren's SyndromeRise Therapeutics · NCT06297213

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07331987Depression · China–RecruitingMoon (Guangzhou) BiotechnologyDec 30, 202660
NCT06297213Sjogren's Syndrome · United States1Not yet recruitingRise TherapeuticsAug 30, 202936
NCT05603403Signs and Symptoms, Digestive · Brazil4CompletedAzidus BrasilMar 15, 2023150
NCT05509725Irritable Bowel Syndrome · Turkey4RecruitingLallemand Health SolutionsNov 2024162
NCT04566549Skin Problems · Taiwan2CompletedGenMont Biotech IncorporationDec 6, 202021
NCT04165551Streptococcus Agalactiae · Spain1TerminatedKerry GroupSep 1, 20203
NCT04125810Stress, Psychological · Ireland, United Kingdom2CompletedInternational Flavors & FragrancesFeb 7, 2020190
NCT03468842Caries · Spain1CompletedKanekaMar 24, 201776
NCT02390687Chronic Periodontitis · India3CompletedNext Gen Pharma India Pvt.Sep 201631
NCT02357771Malocclusion · India3CompletedNext Gen Pharma India Pvt.Aug 201530
NCT02203812Lymphoma, Follicular · India3CompletedCD Pharma India Pvt.Feb 201632
NCT02121665Chronic Periodontitis · India3CompletedCD Pharma India Pvt.Jan 201642
NCT01870362Chronic Periodontitis · India3CompletedCD Pharma India Pvt.Jul 201428
NCT00554099Diverticulitis · United States2CompletedAbbVieMar 2010117

How it is read

Names in the registry

  • “Probiotic”, 6 entries
  • “Probiotic (Inersan)”, 2 entries
  • “R-2487”, 1 entry
  • “Probiatop”, 1 entry
  • “Probiotic formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.